NASDAQ · CTXR
Healthcare · Biotechnology
$0.52
Down-$0.04 (-7.56%)
Updated Oct 6, 2026, 10:16 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CTXR
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
CTXR closed at $0.52 after 20 trading sessions, down 13.41% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $0.5215 | $0.54 | $0.52 | $0.52 | 132.55K |
| Oct 2, 2026 | $0.533 | $0.5489 | $0.5252 | $0.5316 | 80.51K |
| Oct 1, 2026 | $0.5455 | $0.5678 | $0.53 | $0.5402 | 154.96K |
| Sep 30, 2026 | $0.56 | $0.5694 | $0.5304 | $0.531 | 127.49K |
| Sep 29, 2026 | $0.55 | $0.5596 | $0.55 | $0.5545 | 150.26K |
| Sep 28, 2026 | $0.57 | $0.59 | $0.5258 | $0.549 | 279.61K |
| Sep 25, 2026 | $0.5702 | $0.5957 | $0.5665 | $0.5786 | 65.16K |
| Sep 24, 2026 | $0.57 | $0.5848 | $0.56 | $0.5702 | 154.74K |
| Sep 23, 2026 | $0.6039 | $0.61 | $0.5686 | $0.5686 | 223.14K |
| Sep 22, 2026 | $0.57 | $0.6071 | $0.57 | $0.5982 | 215.27K |
| Sep 21, 2026 | $0.5865 | $0.6019 | $0.5723 | $0.5765 | 155.93K |
| Sep 18, 2026 | $0.60 | $0.6044 | $0.5834 | $0.60 | 284.09K |
| Sep 17, 2026 | $0.5712 | $0.60 | $0.5712 | $0.5879 | 245.9K |
| Sep 16, 2026 | $0.56 | $0.5749 | $0.56 | $0.56 | 139.29K |
| Sep 15, 2026 | $0.58 | $0.585 | $0.56 | $0.5601 | 129.57K |
| Sep 14, 2026 | $0.58 | $0.59 | $0.5701 | $0.5731 | 209.4K |
| Sep 11, 2026 | $0.5856 | $0.595 | $0.5805 | $0.581 | 155.63K |
| Sep 10, 2026 | $0.60 | $0.6099 | $0.5805 | $0.5853 | 164.99K |
| Sep 9, 2026 | $0.601 | $0.61 | $0.5807 | $0.582 | 76.92K |
| Sep 8, 2026 | $0.581 | $0.6169 | $0.5804 | $0.6005 | 310.57K |
The latest Smart Investors Daily articles mentioning CTXR.
Company
Market Activity
Research & News
CTXR research
Company profile and research snapshot.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 11, 2026 | D. Boral Capital | Buy | — |
| Dec 4, 2025 | D. Boral Capital | Buy | — |
| Aug 13, 2025 | D. Boral Capital | Buy | — |
| Jun 30, 2025 | D. Boral Capital | Buy | — |
| Jun 10, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 57.5 percent increase over losses of $(0.80) per share from the
Benzinga · Aug 5, 2026
New institutional accounts ordering LYMPHIR increased 78% quarter over quarterLYMPHIR's near-universal payer coverage expands market accessInitial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently
Benzinga · Jul 21, 2026
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by AugustCRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR),
Benzinga · Mar 10, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CTXR.
